NCT02176967 2025-12-22Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk NeuroblastomaChildren's Oncology GroupPhase 3 Active not recruiting621 enrolled
NCT04385277 2025-10-27Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Children's Oncology GroupPhase 2 Active not recruiting41 enrolled 13 charts